Brief: Sagimet’S License Partner Ascletis Announced Acceptance Of New Drug Application For Denifanstat
10/12/2025 12:43
Dec 10 (Reuters) - Sagimet Biosciences Inc SGMT.O: SAGIMET’S LICENSE PARTNER ASCLETIS ANNOUNCED ACCEPTANCE OF NEW DRUG APPLICATION FOR DENIFANSTAT FOR THE TREATMENT OF MODERATE TO SEVERE ACNE BY CHINA’S NATIONAL MEDICAL PRODUCTS ADMINISTRATION SAGIMET BIOSCIENCES INC - GRANTS EXCLUSIVE LICENSE TO DENIFANSTAT FOR CHINA TO ASCLETIS Source text: ID:nGNX1yxwPM Further company coverage: SGMT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage